Thomson Reuters has entered into a definitive agreement to sell its healthcare business to an affiliate of Veritas Capital for $1.25 billion in cash.
This sale is a reversal of Thomson Reuters' January decision to shelve plans to sell its healthcare division "due to economic conditions."
This sale is subject to regulatory approval and customary closing conditions, including the expiration or termination of applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act, and is expected to close in the next few months. The sale is not subject to any financing condition. Veritas has obtained debt financing commitments for the transaction.
The healthcare business provides data, analytics and performance benchmarking technologies and services to hospitals, health systems, employers, health plans, government agencies and healthcare professionals. Its assets include MarketScan, Advantage Suite, Micromedex, CareDiscovery and ActionOI.